CLAIMS

1. An aqueous parenteral nutrition composition, comprising:
deoxycholic acid;
cytidine diphosphate-choline; and
choline alfoscerate,
characterized in that,
the parenteral nutrition further comprises 4.5-5.5% (w/v) phosphatidylcholine, in which combination of the phosphatidycholine with cytidine diphosphate-choline and choline alfoscerate increases choline bioavailability for immediate onset of action.

2. The aqueous parenteral nutrition composition as claimed in claim 1, wherein the composition further comprises of 0.01-0.03% (w/v) tocopherol, 0.01%-0.03% (w/v) nicotinic acid, and 0.01%-0.03% (w/v) adenosine triphosphate.

3. The aqueous parenteral nutrition composition as claimed in claim 1, wherein the concentration of deoxycholic acid is 2.0-4.0% (w/v).

4. The aqueous parenteral nutrition composition as claimed in claim 1, wherein the concentration of cytidine diphosphate-choline is 0.4-0.6% (w/v).

5. The aqueous parenteral nutrition composition as claimed in claim 1, wherein the concentration of choline alfoscerate is 0.4-0.6% (w/v).

6. The aqueous parenteral nutrition composition as claimed in claim 1, wherein the combination of phosphatidycholine with cytidine diphosphate-choline and choline alfoscerate administered parenterally lowers homocysteine level in the blood.

7. A method for preparing an aqueous parenteral nutrition composition (100), comprising steps of:

mixing 2.0%-4.0% (w/v) deoxycholic acid with benzyl alcohol and ethanol (102);

stirring the mixture until a clear solution is obtained (104);

adding 4.5-5.5% (w/v) phosphatidylcholine, cytidine diphosphate-choline and choline alfoscerate to the mixture (106);

stirring the mixture until the phosphatidylcholine, cytidine diphosphate-choline and choline alfoscerate is solubilised (110); and

adjusting specified total volume of the mixture with water and uniformly mixing the resulting aqueous parenteral nutrition composition (112),

characterized in that,

the combination of phosphatidycholine with cytidine diphosphate-choline and choline alfoscerate in the resulting aqueous parenteral nutrition composition increases choline bioavailability for immediate onset of action.

8. The method for preparing an aqueous parenteral nutrition composition as claimed in claim 7, wherein the method further comprises adding 0.01-0.03% (w/v) tocopherol, 0.01%-0.03% (w/v) nicotinic acid and 0.01%-0.03% (w/v) adenosine triphosphate (108).

9. The method for preparing an aqueous parenteral nutrition composition as claimed in claim 7, wherein the concentration of cytidine diphosphate-choline is 0.4-0.6% (w/v).

10. The method for preparing an aqueous parenteral nutrition composition as claimed in claim 7, wherein the concentration of choline alfoscerate is 0.4-0.6% (w/v).